China represents a huge potential opportunity for the pharmaceutical industry in both commercial and research and development spaces. In a recent survey, one of the key themes that emerged was that China’s role in global research and development is changing, and that biopharma firms that develop products in China will be better poised to take full advantage of market opportunities. At the same time, China’s evolving regulatory system, processes, and practices present unique challenges to the industry. Companies must gain a better understanding of the current landscapes, upcoming changes and their impacts, and develop strategies that are effective for China. This article describes various drug development models and the emerging trend in China, and discusses the impact on multinational pharmaceutical companies.
Reprinted with Permission of FDLI.